Central amylin acts as an adiposity signal to control body weight and energy expenditure

Physiology and Behavior

Volumn 101, Issue 1, 2010, Pages 45-52

  Wielinga, Peter Y ^a   Löwenstein, Christian ^a   Muff, Sabine ^a   Munz, Manuela ^a   Woods, Stephen C ^b   Lutz, Thomas A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adiposity signal; Amylin; Energy expenditure; Fasting; Overfeeding

Indexed keywords

AMYLIN; FAT; AMYLOID; PEPTIDE HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; BRAIN THIRD VENTRICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG MECHANISM; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; FOOD INTAKE; HORMONE ACTION; LIPID OXIDATION; MALE; NONHUMAN; OBESITY; OVERNUTRITION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; WEIGHT CONTROL; ANALYSIS OF VARIANCE; ANIMAL; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NONPARAMETRIC TEST; PANCREAS ISLET BETA CELL; PHYSIOLOGY; PSYCHOPHYSIOLOGY; WISTAR RAT;

ADIPOSITY; AMYLOID; ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; ENERGY METABOLISM; INJECTIONS, INTRAVENTRICULAR; INSULIN-SECRETING CELLS; MALE; PEPTIDE HORMONES; RATS; RATS, WISTAR; SATIETY RESPONSE; STATISTICS, NONPARAMETRIC; ISLET AMYLOID POLYPEPTIDE;

EID: 77953914540     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.04.012     Document Type: Article

References (42)

1. Arnelo U., Permert J., Adrian T.E., Larsson J., Westermark P., Reidelberger R.D. Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Am J Physiol 1996, 271:R1654-R1659.
2. Arnelo U., Permert J., Larsson J., Reidelberger R.D., Arnelo C., Adrian T.E. Chronic low dose islet amyloid polypeptide infusion reduces food intake, but does not influence glucose metabolism, in unrestrained conscious rats: studies using a novel aortic catheterization technique. Endocrinology 1997, 138:4081-4085.
3. Banks W.A., Kastin A.J., Maness L.M., Huang W., Jaspan J.B. Permeability of the blood-brain barrier to amylin. Life Sci 1995, 57:1993-2001.
4. Banks W.A., Kastin A.J. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 1998, 19:883-889.
5. Bouali S.M., Wimalawansa S.J., Jolicoeur F.B. In vivo central actions of rat amylin. Regul Pept 1995, 56:167-174.
6. Butler P.C., Chou J., Carter W.B., Wang Y.N., Bu B.H., Chang D., et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990, 39:752-756.
7. Chance W.T., Balasubramaniam A., Zhang F.-S., Fisher J.E. Hyperthermia following the intrahypothalamic administration of amylin. Surg Forum 1992, 42:84-86.
8. Chavez M., Kaiyala K., Madden L.J., Schwartz M.W., Woods S.C. Intraventricular insulin and the level of maintained body weight in rats. Behav Neurosci 1995, 109:528-531.
9. Clementi G., Valerio C., Emmi I., Prato A., Drago F. Behavioral effects of amylin injected intracerebroventricularly in the rat. Peptides 1996, 17:589-591.
10. Crawley J.N., Beinfeld M.C. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983, 302:703-706.
11. Geary N. Endocrine controls of eating: CCK, leptin, and ghrelin. Physiol Behav 2004, 81:719-733.
12. Gebre-Medhin S., Mulder H., Pekny M., Westermark G., Tornell J., Westermark P., et al. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 1998, 250:271-277.
13. Hillebrand J.J.G., Langhans W., Geary N. Validation of computed tomographic estimates of intra-abdominal and subcutaneous adipose tissue in rats and mice. Obesity Res 2010, 18:848-853.
14. Hollander P., Maggs D.G., Ruggles J.A., Fineman M., Shen L., Kolterman O.G., et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obesity Res 2004, 12:661-668.
15. Levin B.E., Dunn-Meynell A.A. Defense of body weight depends on dietary composition and palatability in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2002, 282:R46-R54.
16. Levin B.E., Keesey R.E. Defense of differfing body weight set points in diet-induced obese and resistant rats. Am J Physiol Regul Integr Comp Physiol 1998, 274:R412-R419.
17. Lutz T.A. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 2005, 6:181-189.
18. Lutz T.A., Geary N., Szabady M.M., Del Prete E., Scharrer E. Amylin decreases meal size in rats. Physiol Behav 1995, 58:1197-1202.
19. Lutz T.A., Mollet A., Rushing P.A., Riediger T., Scharrer E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 2001, 25:1005-1011.
20. Lutz T.A., Senn M., Althaus J., Del Prete E., Ehrensperger F., Scharrer E. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 1998, 19:309-317.
21. Lutz T.A. Amylinergic control of food intake. Physiol Behav 2006, 89:465-471.
22. Mack C.M., Wilson J., Athanacio J., Reynolds J., Laugero K., Guss S., et al. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference and body weight. Am J Physiol Regul Integr Comp Physiol 2007, 293(5):R1855-R1863.
23. Mollet A., Gilg S., Riediger T., Lutz T.A. Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. Physiol Behav 2004, 81:149-155.
24. Morley J.E., Suarez M.D., Mattamal M., Flood J.F. Amylin and food intake in mice: effects on motivation to eat and mechanism of action. Pharmacol Biochem Behav 1997, 56:123-129.
25. Muff R., Born W., Lutz T.A., Fischer J.A. Biological importance of the peptides of the calcitonin family as revealed by disruption and transfer of corresponding genes. Peptides 2004, 25:2027-2038.
26. Nedergaard J., Golozoubova V., Matthias A., Asadi A., Jacobsson A., Cannon B. UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency. Biochim Biophys Acta (BBA) - Bioenergetics 2001, 1504:82-106.
27. Olsson M., Herrington M.K., Reidelberger R.D., Permert J., Arnelo U. Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. Peptides 2007, 28(7):1416-1423.
28. Osaka T., Tsukamoto A., Koyama Y., Inoue S. Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides 2008, 29:1028-1035.
29. Osto M., Wielinga P.Y., Alder B., Walser N., Lutz T.A. Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin. Physiol Behav 2007, 91:566-572.
30. Pieber T.R., Roitelman J., Lee Y., Luskey K.L., Stein D.T. Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity. Am J Physiol Endocrinol Metab 1994, 267:E156-E164.
31. Reidelberger R.D., Haver A.C., Arnelo U., Smith D.D., Schaffert C.S., Permert J. Amylin receptor blockade stimulates food intake in rats. Am J Physiol Regul Integr Comp Physiol 2004, 287:R568-R574.
32. Roth J.D., Trevaskis J.L., Wilson J., Lei C., Athanacio J., Mack C., et al. Antiobesity effects of the [beta]-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Int J Obes 2008, 32:1201-1210.
33. Roth J.D., Hughes H., Coffey T., Maier H., Trevaskis J.L., Anderson C.M. Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats. Am J Physiol Endocrinol Metab 2007, 293:E1112-E1117.
34. Roth J.D., Hughes H., Kendall E., Baron A.D., Anderson C.M. Antiobesity effects of the Beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006, 147:5855-5864.
35. Roth J.D., Roland B.L., Cole R.L., Trevaskis J.L., Weyer C., Koda J.E., et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. PNAS 2008, 105:7257-7262.
36. Rushing P.A. Central amylin signaling and the regulation of energy homeostasis. Curr Pharm Des 2003, 9:819-825.
37. Rushing P.A., Hagan M.M., Seeley R.J., Lutz T.A., D'Alessio D.A., Air E.L., et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 2001, 142:5035.
38. Rushing P.A., Hagan M.M., Seeley R.J., Lutz T.A., Woods S.C. Amylin: a novel action in the brain to reduce body weight. Endocrinology 2000, 141:850-853.
39. Rushing P.A., Seeley R.J., Air E.L., Lutz T.A., Woods S.C. Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences. Peptides 2002, 23:985-988.
40. Weir J.B. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949, 109:1-9.
41. Wielinga P.Y., Alder B., Lutz T.A. The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol Behav 2007, 91:212-217.
42. Woods S.C., Seeley R.J. Adiposity signals and the control of energy homeostasis. Nutrition 2000, 16:894-902.